Oncotarget

Research Papers:

ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells

Hyunji Lee _, Hyunjung Lee, Hyunjung Chin, Kyoungmi Kim and Daekee Lee

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:5138-5152. https://doi.org/10.18632/oncotarget.2094

Metrics: PDF 1691 views  |   HTML 2024 views  |   ?  


Abstract

Hyunji Lee1, Hyunjung Lee1, Hyunjung Chin1, Kyoungmi Kim1 and Daekee Lee1,2

1 Department of Life Science Ewha Womans University, Seoul, S. Korea

2 GT5 program, Ewha Womans University, Seoul, S. Korea

Correspondence:

Daekee Lee, email:

Keywords: ERBB3 targeting; Cell cycle arrest; Apoptosis; Bak; Bax

Received: April 4, 2014 Accepted: June 10, 2014 Published: June 11, 2014

Abstract

ERBB3 is an emerging target for cancer therapy among the EGFR family. Contrary to resistance against EGFR and ERBB2 targeting, the genetic inhibition of ERBB3 results in anti-tumorigenic in HCT116 colon cancer cells harboring constitutively active KRAS and PIK3CA mutations. Still, the anti-tumorigenic molecular mechanism has not been defined. We demonstrated in this study that ERBB3 knockdown resulted in cell cycle arrest and activation of Bak and Bax-dependent apoptosis. Apoptosis was irrelevant to the majority of BH3-only pro-apoptotic proteins and correlated with the transcriptional upregulation of Bak and p53-dependent Bax translocation. Treatment with LY294002, a PI3K inhibitor, resulted in cell cycle arrest without apoptosis and a concomitant down-regulation of cap-dependent translation by the suppression of the PI3K/AKT/mTOR pathway. However, the inhibition of cap-dependent translation by ERBB3 knockdown occurred without altering the PI3K/AKT/mTOR pathway. In addition, ERBB3 knockdown-induced cell cycle arrest was observed in most colon cancer cells but was accompanied by apoptosis in p53 wild-type cells. These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2094